Pfizer

Oncology Research and Development Postdoctoral Program

Robert A. Rollins, Ph.D.
Senior Principal Scientist

Education

Undergraduate: B.A. Biology, Colgate University
Graduate: Ph.D. Molecular Biology and Genetics, Cornell University
Postdoctoral Training: Columbia University (Fellowship from the Leukemia and Lymphoma Society)

Research Interests:

My research is focused on understanding the epigenetic mechanisms that drive tumorigenesis and translating this knowledge into innovative  cancer therapies. As a mentor in the Oncology Research Unit, I am motivated by the opportunity to foster the scientific and professional growth of our postdoctoral scientists while guiding the discovery of novel cancer biology.

Selected Publications

Barsotti AM , Ryskin M, Rollins RA. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations, Epigenomics, 7, 687-690 (2015).

Dann SG, Ryskin M, Barsotti AM, Golas J, Shi C, Miranda M, Hosselet C, Lemon L, Lucas J, Karnoub M, Wang F, Myers JS, Garza SJ, Follettie MT, Geles KG, Klippel A, Rollins RA, Fantin VR. Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2, EMBO J, 34, 1773-85 (2015).

Barsotti AM, Ryskin M, Zhong W, Zhang WG, Giannakou A, Loreth C, Diesl V, Follettie M, Golas J, Lee M, Nichols T, Fan C, Li G, Dann S, Fantin VR, Arndt K, Verhelle D, Rollins RA. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth, Oncotarget, 6, 2928-38 (2015).

Hebbard L, Cecena G, Golas J, et al. Control of mammary tumor differentiation by SKI-606 (bosutinib), Oncogene, 30, 301-312 (2011).